Overview

A Clinical Study in Patients With High-risk Recurrent Primary Hepatocellular Carcinoma Using Autologous TILs

Status:
Active, not recruiting
Trial end date:
2022-10-31
Target enrollment:
Participant gender:
Summary
Early clinical trials on evaluating the tolerance, safety and efficacy of autologous TILs in high-risk recurrent primary hepatocellular carcinoma
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
CAR-T (Shanghai) Cell Biotechnology Co., Ltd.
Collaborator:
Eastern Hepatobiliary Surgery Hospital